Cartesian Therapeutics Inc Stock

$17.74-0.02 (-0.11%)
Updated Jul 12, 2024
RNAC Price
Fair Value Price
Market Cap
52 Week Low
52 Week High
Dividend Yield
Gross Margin
Operating Margin
Profit Margin
Debt to Equity
Operating Cash Flow
Next Earnings
Aug 15, 2024
Next Dividend

RNAC Overview

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RNAC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RNAC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RNAC is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
RNAC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more RNAC due diligence checks available for Premium users.

Be the first to know about important RNAC news, forecast changes, insider trades & much more!



RNAC fair value

Fair Value of RNAC stock based on Discounted Cash Flow (DCF)
Fair Value
Undervalued by
RNAC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RNAC price to earnings (PE)

For valuing profitable companies with steady earnings

RNAC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

RNAC's financial health

Profit margin

Net Income
Profit Margin
RNAC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RNAC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Debt to equity
RNAC's short-term assets ($111.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RNAC's long-term liabilities ($405.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RNAC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RNAC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

RNAC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RNAC vs Biotech Stocks

TickerMarket Cap1d %P/EP/B

Cartesian Therapeutics Stock FAQ

What is Cartesian Therapeutics's quote symbol?

(NASDAQ: RNAC) Cartesian Therapeutics trades on the NASDAQ under the ticker symbol RNAC. Cartesian Therapeutics stock quotes can also be displayed as NASDAQ: RNAC.

If you're new to stock investing, here's how to buy Cartesian Therapeutics stock.

What is the 52 week high and low for Cartesian Therapeutics (NASDAQ: RNAC)?

(NASDAQ: RNAC) Cartesian Therapeutics's 52-week high was $42.60, and its 52-week low was $11.67. It is currently -58.36% from its 52-week high and 52.08% from its 52-week low.

How much is Cartesian Therapeutics stock worth today?

(NASDAQ: RNAC) Cartesian Therapeutics currently has 17,796,053 outstanding shares. With Cartesian Therapeutics stock trading at $17.74 per share, the total value of Cartesian Therapeutics stock (market capitalization) is $315.70M.

Cartesian Therapeutics stock was originally listed at a price of $420.00 in Jun 22, 2016. If you had invested in Cartesian Therapeutics stock at $420.00, your return over the last 8 years would have been -95.78%, for an annualized return of -32.67% (not including any dividends or dividend reinvestments).

How much is Cartesian Therapeutics's stock price per share?

(NASDAQ: RNAC) Cartesian Therapeutics stock price per share is $17.74 today (as of Jul 12, 2024).

What is Cartesian Therapeutics's Market Cap?

(NASDAQ: RNAC) Cartesian Therapeutics's market cap is $315.70M, as of Jul 14, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cartesian Therapeutics's market cap is calculated by multiplying RNAC's current stock price of $17.74 by RNAC's total outstanding shares of 17,796,053.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.